Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA

GlobeNewswire 9 days ago

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

GlobeNewswire December 20, 2024

Altamira Therapeutics Provides Update on Nasdaq Listing

GlobeNewswire October 4, 2024

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

GlobeNewswire September 27, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

GlobeNewswire September 24, 2024

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

GlobeNewswire September 20, 2024

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

GlobeNewswire September 19, 2024

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

GlobeNewswire September 17, 2024

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

GlobeNewswire September 16, 2024

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

GlobeNewswire September 3, 2024

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

GlobeNewswire August 23, 2024

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

GlobeNewswire August 16, 2024

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

GlobeNewswire August 12, 2024

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

GlobeNewswire July 19, 2024

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

GlobeNewswire June 20, 2024

Altamira Therapeutics Provides Business Update

GlobeNewswire May 28, 2024

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

GlobeNewswire May 23, 2024

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

GlobeNewswire May 1, 2024

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

GlobeNewswire April 24, 2024

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

GlobeNewswire April 10, 2024